TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 1 filers reported holding TRAVERE THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,579 | -33.5% | 288,654 | +14.3% | 0.00% | 0.0% |
Q2 2023 | $3,879 | -15.0% | 252,583 | +24.6% | 0.00% | 0.0% |
Q1 2023 | $4,561 | +17.4% | 202,786 | +9.7% | 0.00% | 0.0% |
Q4 2022 | $3,885 | -99.9% | 184,786 | +35.0% | 0.00% | -50.0% |
Q3 2022 | $3,374,000 | +445.1% | 136,913 | +435.7% | 0.00% | – |
Q2 2022 | $619,000 | -50.9% | 25,556 | -47.7% | 0.00% | -100.0% |
Q1 2022 | $1,261,000 | – | 48,901 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Finepoint Capital LP | 875,221 | $19,683,720 | 7.52% |
Deep Track Capital, LP | 6,147,268 | $138,252,057 | 5.68% |
Kynam Capital Management, LP | 1,563,595 | $35,165,252 | 4.54% |
GREAT POINT PARTNERS LLC | 1,003,000 | $22,557,470 | 4.43% |
ARMISTICE CAPITAL, LLC | 7,148,000 | $160,758,520 | 2.32% |
HighVista Strategies LLC | 121,834 | $2,740,047 | 2.23% |
MPM BioImpact LLC | 313,642 | $7,053,809 | 1.83% |
Sofinnova Investments, Inc. | 1,263,721 | $28,421,085 | 1.82% |
Octagon Capital Advisors LP | 495,000 | $11,132,550 | 1.60% |
SECTORAL ASSET MANAGEMENT INC | 358,613 | $8,065,206 | 1.55% |